- Home
- GSBC vs SNY Comparison
GSBC vs SNY Comparison
Compare GSBC & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GSBC | SNY |
|---|---|---|
| Founded | 1923 | 1994 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 627.5M | 119.4B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | GSBC | SNY |
|---|---|---|
| Price | $64.13 | $48.35 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 5 |
| Target Price | $59.50 | ★ $61.50 |
| AVG Volume (30 Days) | 56.2K | ★ 2.8M |
| Earning Date | 01-20-2026 | 01-29-2026 |
| Dividend Yield | 2.62% | ★ 3.33% |
| EPS Growth | 18.31 | ★ 105.93 |
| EPS | 6.00 | ★ 8.67 |
| Revenue | $228,683,000.00 | ★ $53,890,648,839.00 |
| Revenue This Year | N/A | $2.48 |
| Revenue Next Year | N/A | $6.47 |
| P/E Ratio | $11.04 | ★ $5.53 |
| Revenue Growth | ★ 7.86 | N/A |
| 52 Week Low | $47.58 | $44.62 |
| 52 Week High | $66.59 | $60.12 |
Technical Indicators
Market Signals| Indicator | GSBC | SNY |
|---|---|---|
| Relative Strength Index (RSI) | 62.18 | 43.39 |
| Support Level | $65.08 | $46.97 |
| Resistance Level | $66.59 | $48.41 |
| Average True Range (ATR) | 1.24 | 0.70 |
| MACD | 0.22 | -0.09 |
| Stochastic Oscillator | 63.58 | 35.55 |
Price Performance
Historical ComparisonAbout GSBC Great Southern Bancorp Inc.
Great Southern Bancorp Inc is a bank holding company. It is principally engaged in the business of originating residential and commercial real estate loans, construction loans, commercial business loans, and consumer loans. The bank provides various services such as Business Banking, Merchant Services, Debit and Credit cards, Online Banking, Mobile Banking, VIP Banking, Overdraft Protection, and various other related services. It operates into a single segment which is Community Banking.
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.